medigraphic.com

2010, Number 4

<< Back Next >>

Enf Infec Microbiol 2010; 30 (4)

Prevalence of depression in HIV/AIDS patients in the Hospital General de Zona # 11(IMSS), Lic. Ignacio Díaz López

Galindo SJ, Ortega RM

Language: Spanish
References: 24
Page: 129-133
PDF size: 86.72 Kb.


ABSTRACT


ANTECEDENTS. At present patients with HIV infection live longer. Therefore, psychiatric disorders are most common. Depression has been associated with increase in mortality, less antiretroviral treatment adherence and low life quality. Around the world, among HIV patients, depression has prevalence from 21% to 97%. These reasons took us to investigate the prevalence of this disorder in our population.
MATERIAL AND METHODS. We made a survey of the HIV patients who were attended at the Hospital General de Zona #11 (IMSS). We used the Depressive Syndrome Clinical Questionnaire developed by Calderon-Narváez. For each patient we took the history of type of scheme, number of the scheme, civil status, and viral load. We compared the proportions of patients between those data and the presence of depression, using the Z test, with an alpha confidence of 0.05.
RESULTS. 160 HIV patients were studied. 70.63% had normal range punctuation, 10.63% with anxiety, 18.13% with mild depression, and 0.63% with severe depression. There was no statistical significance between the type of treatment and depression, but we observed a statistical significant relationship with viral load and also with the number of scheme.
CONCLUSION. We observed an 18.76% prevalence of depression in our patients.


REFERENCES

  1. Bing EG, Burnam MA, Longshore D, et al. “Psychiatric disorders and drug use among Human Immunodefi-ciency Virus–Infected adults in the United States”. Arch Gen Psychiatry 2001; 58: 721-728.

  2. Eller LS. “Depressive symptoms in HIV Disease”. Nurs Clin N Am 2006; 41: 437-453.

  3. Dew MA, Becker JT, Sanchez J, et al. “Prevalence and predictors of depressive, anxiety and substance use disorders in HIV-infected and uninfected men: a longitu-dinal evaluation”. Psychol Med 1997; 27: 395-409.

  4. Jin H, Atkinson H, Yu X, et al. “Depression and sui-cidality in HIV/AIDS in China”. J Affect Disord 2006; 94: 269-275.

  5. Teva I, Bermudez M, Hernández-Quero J, Buela-Casal G. “Evaluación de la depresión, ansiedad e ira en pa-cientes con VIH/SIDA”. Salud Mental 2005; 5: 40-49.

  6. Weiser SD, Riley ED, Ragland K, et al. Brief report: Fac-tors associated with depression among homeless and marginally housed HIV-lnfected men in San Francisco”. J Gen Intern Med 2006; 21: 61-64.

  7. Berg C, Michelson SE, Safren SA. “Behavioral aspects of HIV care: Adherence, depression, substance use, and HIV-Transmission behaviors”. Infect Dis Clin N Am 2007; 21: 181-200.

  8. Asch SM, Kilbourne AM, Gifford AL, et al. “Underdiag-nosis of depression in HIV. Who are we missing?”. J Gen Intern Med 2003; 18: 450-460.

  9. Ferrando SJ, Freyberg Z. “Neuropsychiatric aspects of infectious diseases”. Crit Care Clin 2008; 24: 889-919.

  10. Wells PB. “The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS”. J Antimicrob Chemother 2009; 63: 636-640.

  11. Ickovics JR, Hamburger ME, Vlahov D, et al. “Mortal-ity, CD4 cell count decline, and depressive symptoms among HIV-Seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study”. JAMA 2001; 285: 1566-1474.

  12. Cook JA, Grey D, Burke J, et al. “Depressive symptoms and AIDS-Related mortality among a multisite cohort of HIV-Positive women”. Am J Public Health 2004; 94: 1466-1474.

  13. Leserman J. “Role of Depression, Stress, and Trauma in HIV Disease Progression”. Psychosom Med 2008; 70: 539-545.

  14. Vazquez-Justo E, Rodríguez Álvarez M, Ferraces-Otero M. “Influence of depressed mood on neuropsychologic performance in HIV-seropositive drug users”. Psychia-try Clin Neurosci 2003; 57: 251-258.

  15. Repetto MJ, Petitto JM. “Psychopharmacology in HIV-Infected patients”. Psychosom Med 2008; 70: 585-592.

  16. Olatunji BO, Mimiaga MJ, O’Cleirigh C, Safren SA. “A review of treatment studies of depression in HIV”. Top HIV Med 2006; 14: 112-124.

  17. Weber R, Christen L, Tschopp S, et al. “Effect of indi-vidual cognitive behavior intervention on adherence to antiretroviral therapy: prospective randomized trial”. Antivir Ther 2004; 9: 85-95.

  18. Calderón-Narváez G. “Cuestionario clínico para el diag-nóstico de los cuadros depresivos”. Rev. Med IMSS 1992; 30: 377-380.

  19. Morales-Ramírez M, Ocampo-Andréyeva V, De la Mo-ra L, Alvarado-Calvillo R. “Validez y confiabilidad del cuestionario clínico del síndrome depresivo”. Arch Neurocien (Mex) 1996; 111-115.

  20. Poupard M, Ngom G, Thiam D, et al. “Quality of life and depression among HIV-infected patients receiving efa-virenz or protease inhibitor-based therapy in Senegal”. HIV Medicine 2007; 8: 92-95.

  21. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B,Reynes J. “Long-term assessment of neuropsychia-tric adverse reactions associated with efavirenz”. HIV Med 2003; 4: 62-66.

  22. Gordillo V, del Amo J, Soriano V, et al. “Sociodemo-graphic and psychological variables influencing adher-ence to antiretroviral therapy”. AIDS 1999; 13: 1763-9.

  23. Pence BW, Miller WC, Gaynes BN, et al. “Psychiatric ill“P ness and virologic response in patients initiating highly active antiretroviral therapy”. J Acquir Immune Defic Syndr 2007; 44: 159-66.

  24. Mugavero M, Ostermann J, Whetten K, et al. “Barriers to antiretroviral adherence: the importance of depres-sion, abuse, and other traumatic events”. AIDS Patient Care STDS 2006; 20: 418-28.




2020     |     www.medigraphic.com